Please wait while the formulary information is being retrieved.
NEOMYCIN SULFATE (NEOMYCIN SULFATE)
- Preoperative bowel preparation
- Hepatic coma
- Hepatic encephalopathy
neomycin 500 mg tablet
- 4 tablets (2,000 mg) by oral route 2 times per day
500 mg tablet
- 4 tablets (2,000 mg) by oral route 2 times per day
Hepatic coma
- 4 tablets (2,000 mg) by oral route 2 times per day
- 4 tablets (2,000 mg) by oral route 3 times per day
- 4 tablets (2,000 mg) by oral route 4 times per day
- 6 tablets (3,000 mg) by oral route 2 times per day
- 6 tablets (3,000 mg) by oral route 3 times per day
- 6 tablets (3,000 mg) by oral route 4 times per day
Hepatic encephalopathy
- 4 tablets (2,000 mg) by oral route 2 times per day
- 4 tablets (2,000 mg) by oral route 3 times per day
- 4 tablets (2,000 mg) by oral route 4 times per day
- 6 tablets (3,000 mg) by oral route 2 times per day
- 6 tablets (3,000 mg) by oral route 3 times per day
- 6 tablets (3,000 mg) by oral route 4 times per day
Preoperative bowel preparation
- 2 tablets (1,000 mg) by oral route at 1 p.m.; 2 tablets (1,000 mg) at 2 p.m. And 2 tablets (1,000 mg) at 11 p.m. The day before surgery
- typhoid vaccine
- Vivotif Berna Vaccine
Contraindicated
- abobotulinumtoxinA
- Anectine
- atracurium
- Botox
- Botox Cosmetic
- cisatracurium
- Compound 347
- Dysport
- enflurane
- Forane
- incobotulinumtoxinA
- isoflurane
- Myobloc
- Nimbex
- onabotulinumtoxinA
- pancuronium
- Quelicin
- rimabotulinumtoxinB
- rocuronium
- succinylcholine chloride
- Terrell
- vecuronium bromide
- Xeomin
- Zemuron
Severe
Moderate
- ampicillin sodium
- ampicillin-sulbactam
- Bicillin C-r
- Bicillin L-a
- bumetanide
- Cedax
- cefaclor
- cefadroxil
- cefazolin
- cefazolin in dextrose (iso-os)
- cefdinir
- cefepime
- cefepime in dextrose 5 %
- cefepime in dextrose,iso-osm
- cefotaxime
- cefotetan
- cefotetan in dextrose, iso-osm
- cefoxitin
- cefoxitin in dextrose 3.9 %
- cefoxitin in dextrose, iso-osm
- cefpodoxime
- cefprozil
- ceftazidime
- ceftazidime in D5W
- ceftazidime-dextrose (iso-osm)
- ceftibuten
- Ceftin
- ceftriaxone
- ceftriaxone in dextrose,iso-os
- cefuroxime axetil
- cefuroxime in sterile water
- cefuroxime sodium
- cefuroxime-dextrose (iso-osm)
- cephalexin
- Claforan
- Demadex
- Digox
- digoxin
- ethacrynate sodium
- Fortaz
- Fortaz In Dextrose 5 %
- furosemide
- Keflex
- Lanoxin
- Lasix
- Maxipime
- Mefoxin In Dextrose (iso-osm)
- nafcillin
- nafcillin in dextrose iso-osm
- oxacillin
- oxacillin in dextrose(iso-osm)
- penicillin G benzathine
- penicillin G benzathine & proc
- penicillin G pot in dextrose
- penicillin G potassium
- penicillin G procaine
- penicillin G sodium
- Pfizerpen-g
- piperacillin-tazobactam
- piperacillin-tazobactam-dextrs
- Rocephin
- Sodium Edecrin
- Tazicef
- ticarcillin-clavulanate
- Timentin
- torsemide
- Unasyn
- Zinacef
- Zinacef In Sterile Water
- Zosyn
- Zosyn In Dextrose (iso-osm)
- Gastrointestinal obstruction
- Ulceration of intestine
Contraindicated
- Auditory neurotoxicity
- Disorder of the 8th cranial nerve
- Hypovolemia
- Kidney disease with reduction in GFR
- Myasthenia gravis
- Parkinsonism
- Pregnancy
Severe
Moderate
- None
NEOMYCIN SULFATE (NEOMYCIN SULFATE)
- Preoperative bowel preparation
- Hepatic coma
- Hepatic encephalopathy
- None
- Diarrhea
- Mouth irritation
- Nausea
- Rectal irritation
- Rectal pain
- Vomiting
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Allergic dermatitis
- Malabsorption states
- Nephrotoxicity
- Neuromuscular blockade
- Ototoxicity
- Skin rash
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Neomycin (Oral)
Safety and efficacy age < 18 years not established. Manufacturer recommends limit treatment to 3 weeks.
- 1 Day – 18 Years
- Safety and efficacy age < 18 years not established. Manufacturer recommends limit treatment to 3 weeks.
Neomycin Sulfate (systemic)
- Severity Level:
D
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Neomycin
Insufficient data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Neomycin
Monitor renal function and drug levels. Hearing loss is possible even with normal peak and trough levels.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication can rarely cause serious kidney problems and nerve damage, resulting in permanent hearing loss (including deafness or decreased hearing) and balance problems. These serious side effects may occur even in people without kidney problems and taking usual doses. Hearing problems may occur long after neomycin has been stopped.<br /><br />The risk is increased if you are older, already have kidney disease, or if you have a severe loss of body water (dehydration). Your risk is also increased if you receive high doses, or with longer use of this medication. Tell your doctor right away if you notice ringing/roaring sounds in the ears, hearing loss, dizziness, or an unusual decrease in the amount of your urine.<br /><br /> Severe muscle and breathing problems may also rarely occur. Careful monitoring by your doctor will reduce the risk of these side effects. Monitoring may include hearing, kidney, and urine tests.<br /><br /> Avoid other medications that may increase your risk for these serious side effects if taken together with neomycin. See also Drug Interactions section.
| Hepatic coma | |
| B15.0 | Hepatitis A with hepatic coma |
| B16.0 | Acute hepatitis B with delta-agent with hepatic coma |
| B16.2 | Acute hepatitis B without delta-agent with hepatic coma |
| B17.11 | Acute hepatitis C with hepatic coma |
| B19.0 | Unspecified viral hepatitis with hepatic coma |
| B19.11 | Unspecified viral hepatitis B with hepatic coma |
| B19.21 | Unspecified viral hepatitis C with hepatic coma |
| K70.41 | Alcoholic hepatic failure with coma |
| K71.11 | Toxic liver disease with hepatic necrosis, with coma |
| K72.01 | Acute and subacute hepatic failure with coma |
| K72.11 | Chronic hepatic failure with coma |
| K72.91 | Hepatic failure, unspecified with coma |
| Hepatic encephalopathy | |
| B15.0 | Hepatitis A with hepatic coma |
| B16.0 | Acute hepatitis B with delta-agent with hepatic coma |
| B16.2 | Acute hepatitis B without delta-agent with hepatic coma |
| B17.11 | Acute hepatitis C with hepatic coma |
| B19.0 | Unspecified viral hepatitis with hepatic coma |
| B19.11 | Unspecified viral hepatitis B with hepatic coma |
| B19.21 | Unspecified viral hepatitis C with hepatic coma |
| K70.41 | Alcoholic hepatic failure with coma |
| K71.11 | Toxic liver disease with hepatic necrosis, with coma |
| K72.01 | Acute and subacute hepatic failure with coma |
| K72.11 | Chronic hepatic failure with coma |
| K72.90 | Hepatic failure, unspecified without coma |
| K72.91 | Hepatic failure, unspecified with coma |
| 0-9 | A-Z |
|---|---|
| B15.0 | Hepatitis A with hepatic coma |
| B15.0 | Hepatitis A with hepatic coma |
| B16.0 | Acute hepatitis B with delta-agent with hepatic coma |
| B16.0 | Acute hepatitis B with delta-agent with hepatic coma |
| B16.2 | Acute hepatitis B without delta-agent with hepatic coma |
| B16.2 | Acute hepatitis B without delta-agent with hepatic coma |
| B17.11 | Acute hepatitis C with hepatic coma |
| B17.11 | Acute hepatitis C with hepatic coma |
| B19.0 | Unspecified viral hepatitis with hepatic coma |
| B19.0 | Unspecified viral hepatitis with hepatic coma |
| B19.11 | Unspecified viral hepatitis B with hepatic coma |
| B19.11 | Unspecified viral hepatitis B with hepatic coma |
| B19.21 | Unspecified viral hepatitis C with hepatic coma |
| B19.21 | Unspecified viral hepatitis C with hepatic coma |
| K70.41 | Alcoholic hepatic failure with coma |
| K70.41 | Alcoholic hepatic failure with coma |
| K71.11 | Toxic liver disease with hepatic necrosis, with coma |
| K71.11 | Toxic liver disease with hepatic necrosis, with coma |
| K72.01 | Acute and subacute hepatic failure with coma |
| K72.01 | Acute and subacute hepatic failure with coma |
| K72.11 | Chronic hepatic failure with coma |
| K72.11 | Chronic hepatic failure with coma |
| K72.90 | Hepatic failure, unspecified without coma |
| K72.91 | Hepatic failure, unspecified with coma |
| K72.91 | Hepatic failure, unspecified with coma |
Formulary Reference Tool